SGLT2 抑制剂对心肾保护的分子机制。
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.
机构信息
Division of Nephrology, Department of Medicine, Cardinal-Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City 234, Taiwan.
Graduate Institute of Clinical Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
出版信息
Int J Mol Sci. 2020 Oct 22;21(21):7833. doi: 10.3390/ijms21217833.
The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre- and post- glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism.
钠-葡萄糖协同转运蛋白 2 抑制剂（SGLT2i）的发展拓宽了治疗糖尿病的治疗策略。通过抑制近端肾小管对钠和葡萄糖的重吸收，改善胰岛素抵抗和利钠作用，降低了糖尿病（DM）患者的心血管死亡率。已知 SGLT2i 还通过调节肾小球前和后血管张力来降低肾小球内高压，从而提供肾脏保护作用。SGLT2i 的应用还在分子水平上提供了代谢和血流动力学方面的益处。最近的 DAPA-CKD 试验和 EMPEROR-Reduced 试验提供了肾脏和心脏保护的临床证据，甚至在非糖尿病患者中也是如此。因此，本综述的目的是从分子机制阐明 SGLT2i 的血流动力学和代谢调节作用。
Zotero 插件